Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in <em>in vivo</em> and <em>in vitro</em>

Zhao,Yan; Chen,Yuetong; Wang,Jing; Liu,Liang

doi:10.3892/ol.2021.12625

Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro

Authors:
- Yan Zhao
- Yuetong Chen
- Jing Wang
- Liang Liu
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: March 10, 2021 https://doi.org/10.3892/ol.2021.12625
Article Number: 364

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is one of the main factors limiting the efficacy of chemotherapy in patients with laryngeal cancer; thus, it is important to investigate the drug resistance of laryngeal cancer. In the present study, the mechanism of the regulation of drug resistance in laryngeal cancer cells by ATP-binding transporter G2 (ABCG2) that is present in the extracellular vesicles (EVs) released by drug-resistant cells was studied in vivo and in vitro. A cisplatin (CDDP)-resistant cell line (AMC-HN-8/CDDP) was established from AMC-HN-8 cells by continuous exposure to increasing concentrations of CDDP. The EVs extracted from the culture medium of AMC-HN-8/CDDP and AMC-HN-8 cells were termed EVs1 and EVs2, respectively. Following 48-h treatment of AMC-HN-8 cells with EVs1 or EVs2, the cells were designated as AMC-HN-8-EVs1 or AMC-HN-8-EVs2. Nude mice bearing AMC-HN-8-EVs1 and AMC-HN-8 cell-derived xenograft tumors were established to detect the effects of EVs on drug resistance. The resistance index of AMC-HN-8/CDDP cells to CDDP was 5.60, which was determined by the MTT assay. The mRNA and protein expression levels of ABCG2 in AMC-HN-8/CDDP cells and EVs1 were significantly higher compared with those in AMC-HN-8 cells and EVs2, respectively (P<0.01). The ABCG2 mRNA and protein levels, and the proliferation index of AMC-HN-8-EVs1 cells were significantly higher compared with those of AMC-HN-8-EVs2 and AMC-HN-8 cells (P<0.01), whereas the apoptotic rate was significantly lower (P<0.01). The mean volume of subcutaneous tumor xenografts in the test group (inoculated with AMC-HN-8-EVs1 cells and intraperitoneally injected with 3 mg/kg CDDP) was significantly higher compared with that in the control group (inoculated with AMC-HN-8 cells and intraperitoneally injected with 3 mg/kg CDDP) (P<0.01), whereas the apoptotic rate of tumor cells was significantly lower (P<0.01). The ABCG2 mRNA and the protein expression levels in the tumor cells of the test group were significantly higher compared with those in the blank (inoculated with AMC-HN-8 cells and was intraperitoneally injected with normal saline) and control groups (P<0.01). The high expression levels of ABCG2 in laryngeal carcinoma cells affected the drug resistance of the cells. The EVs released by drug-resistant cells upregulated the expression of ABCG2 and induced drug resistance in laryngeal carcinoma cells, which may be dependent on the ABCG2 gene carried by the EVs.

View Figures

View References

1	He Y, Liang D, Li D, Shan B, Zheng R, Zhang S, Wei W and He J: Incidence and mortality of laryngeal cancer in China, 2015. Chin J Cancer Res. 32:10–17. 2020. View Article : Google Scholar : PubMed/NCBI
2	Tang D, Tao L, Zhou L, Zhang M, Wu H, Li X, Chen X, Li C, Xie M and Cheng L: Retrospective analysis of 659 laryngeal squamous cell carcinoma patients treated with open laryngeal function-preserving operations. Acta Otolaryngol. 138:1043–1050. 2018. View Article : Google Scholar : PubMed/NCBI
3	Zhou J, Zhou L, Tao L, Zhang M, Wu H, Chen X, Li X, Li C and Gong H: Oncological outcomes of surgical treatment for T3 supraglottic laryngeal squamous cell carcinoma patients. Acta Otolaryngol. 138:1028–1034. 2018. View Article : Google Scholar : PubMed/NCBI
4	Adeel M, Faisal M, Rashid A, Rasheed S, Hussain R, Malik KI, Hameed MY and Jamshed A: Outcomes of definitive radiotherapy for early laryngeal cancer in terms of survival and patterns of failure. J Laryngol Otol. 133:1087–1091. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ozdemir Y and Topkan E: Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy. Indian J Cancer. 56:29–34. 2019. View Article : Google Scholar : PubMed/NCBI
6	Hsieh CH, Lin CY, Hsu CL, Fan KH, Huang SF, Liao CT, Lee LY, Ng SK, Yen TC, Chang JT, et al: Incorporation of Astragalus polysaccharides injection during concurrent chemoradiotherapy in advanced pharyngeal or laryngeal squamous cell carcinoma: Preliminary experience of a phase II double-blind, randomized trial. J Cancer Res Clin Oncol. 146:33–41. 2020. View Article : Google Scholar : PubMed/NCBI
7	Spector ME, Rosko AJ, Swiecicki PL, Chad Brenner J and Birkeland AC: From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. Oral Oncol. 86:200–205. 2018. View Article : Google Scholar : PubMed/NCBI
8	Zeng H, Huang Y, Chen L, Li H and Ma X: Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer. Int Immunopharmacol. 85:1066222020. View Article : Google Scholar : PubMed/NCBI
9	Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003. View Article : Google Scholar : PubMed/NCBI
10	Li R, Chen S, Zhan J, Li X, Liu W, Sheng X, Lu Z, Zhong R, Chen L, Luo X, et al: Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation. Cell Death Dis. 11:412020. View Article : Google Scholar : PubMed/NCBI
11	Zhu M, Yin F, Yang L, Chen S, Chen R, Zhou X, Jing W, Fan X, Jia R, Wang H, et al: Contribution of TIP30 to chemoresistance in laryngeal carcinoma. Cell Death Dis. 5:e14682014. View Article : Google Scholar : PubMed/NCBI
12	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
13	Feng SL, Luo HB, Cai L, Zhang J, Wang D, Chen YJ, Zhan HX, Jiang ZH and Xie Y: Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: In vitro and in vivo study. J Ginseng Res. 44:247–257. 2020. View Article : Google Scholar : PubMed/NCBI
14	Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J, Chen X and Shi L: Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2. Mediators Inflamm. 2019:72414182019. View Article : Google Scholar : PubMed/NCBI
15	Sinha BK, Perera L and Cannon RE: Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells. Biomed Pharmacother. 120:1094682019. View Article : Google Scholar : PubMed/NCBI
16	Xie ZY, Wang FF, Xiao ZH, Liu SF, Tang SL and Lai YL: Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1. J Biochem. 167:557–564. 2020. View Article : Google Scholar : PubMed/NCBI
17	Liu L, Zuo LF and Guo JW: ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance. Mol Med Rep. 9:1299–1304. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Liu L, Chen Y, Du Y, Wang J and Liu J: Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate. Pathol Res Pract. 214:1467–1473. 2018. View Article : Google Scholar : PubMed/NCBI
19	He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y, Wei B, Liu F, Deng X, Chen H, et al: Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Mol Oncol. 13:403–421. 2019. View Article : Google Scholar : PubMed/NCBI
20	Kim CK, Oh S, Kim SJ, Leem SH, Heo J and Chung SH: Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma. Genes Genomics. 40:381–388. 2018. View Article : Google Scholar : PubMed/NCBI
21	Liang YL, Wu CH, Kang CY, Lin CN, Shih NY, Lin SH, Chen YC and Hsu KF: Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2. J Cancer. 10:6025–6036. 2019. View Article : Google Scholar : PubMed/NCBI
22	Das S, Mukherjee P, Chatterjee R, Jamal Z and Chatterji U: Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles. Mol Cancer Ther. 18:680–692. 2019. View Article : Google Scholar : PubMed/NCBI
23	Shen B, Dong P, Li D and Gao S: Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med. 2:1151–1157. 2011. View Article : Google Scholar : PubMed/NCBI
24	Denton AE, Roberts EW and Fearon DT: Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol. 1060:99–114. 2018. View Article : Google Scholar : PubMed/NCBI
25	Wu T and Dai Y: Tumor microenvironment and therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
26	Akhtar M, Haider A, Rashid S and Al-Nabet ADMH: Paget's ‘Seed and Soil’ Theory of Cancer Metastasis: An Idea Whose Time has Come. Adv Anat Pathol. 26:69–74. 2019. View Article : Google Scholar : PubMed/NCBI
27	Hayashida T, Jinno H and Kitagawa Y: Epithelial-mesenchymal transition and tumor microenvironment propose the seed and soil theory of the present age. Nihon Rinsho. 70 (Suppl 7):203–207. 2012.(In Japanese). PubMed/NCBI
28	Mulcahy LA, Pink RC and Carter DR: Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. Aug 4–2014.doi: 10.3402/jev.v3.24641. View Article : Google Scholar : PubMed/NCBI
29	Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, Gao F, Narain NR, DiFiglia M, Kiebish MA, et al: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5:325702016. View Article : Google Scholar : PubMed/NCBI
30	Lawson C, Vicencio JM, Yellon DM and Davidson SM: Microvesicles and exosomes: New players in metabolic and cardiovascular disease. J Endocrinol. 228:R57–R71. 2016. View Article : Google Scholar : PubMed/NCBI
31	Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H and Lyden D: Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis. Cancer Cell. 30:836–848. 2016. View Article : Google Scholar : PubMed/NCBI
32	Lindenbergh MFS and Stoorvogel W: Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu Rev Immunol. 36:435–459. 2018. View Article : Google Scholar : PubMed/NCBI
33	Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C and Toren P: Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Prostate. 79:1767–1776. 2019. View Article : Google Scholar : PubMed/NCBI
34	Wang Y, Dong L, Zhong H, Yang L, Li Q, Su C, Gu W and Qian Y: Extracellular vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport. Int J Biol Sci. 15:2110–2118. 2019. View Article : Google Scholar : PubMed/NCBI
35	Takahashi K, Yan IK, Wood J, Haga H and Patel T: Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 12:1377–1387. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhou T, Li Y, Yang L, Liu L, Ju Y and Li C: Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol Rep. 37:388–398. 2017. View Article : Google Scholar : PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Leung HW, Lau EYT, Leung CON, Lei MML, Mok EHK, Ma VWS, Cho WCS, Ng IOL, Yun JP, Cai SH, et al: NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. Cancer Lett. 476:48–56. 2020. View Article : Google Scholar : PubMed/NCBI
39	Zhong P, Chen X, Guo R, Chen X, Chen Z, Wei C, Li Y, Wang W, Zhou Y and Qin L: Folic acid-modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance. Mol Pharm. 17:1114–1126. 2020. View Article : Google Scholar : PubMed/NCBI
40	Paškevičiūtė M and Petrikaitė V: Overcoming transporter-mediated multidrug resistance in cancer: Failures and achievements of the last decades. Drug Deliv Transl Res. 9:379–393. 2019. View Article : Google Scholar : PubMed/NCBI
41	Ganapathi RN and Ganapathi MK: Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol. 4:892013. View Article : Google Scholar : PubMed/NCBI
42	Nagraj J, Chatterjee S, Pal T, Sakpal AS, Gota V, Ramaa CS and Ray P: A novel series of di-fluorinated propanedione derivatives synergistically augment paclitaxel mediated caspase 3 activation in ovarian cancer cells. J Cancer Res Ther. 10:701–709. 2014.PubMed/NCBI
43	Ambjorner SEB, Wiese M, Kohler SC, Svindt J, Lund XL, Gajhede M, Saaby L, Brodin B, Rump S, Weigt H, et al: The pyrazolo[3,4-d]pyrimidine derivative, SCO-201, reverses multidrug resistance mediated by ABCG2/BCRP. Cells. 9:6132020. View Article : Google Scholar
44	Gao Q, Li XX, Xu YM, Zhang JZ, Rong SD, Qin YQ and Fang J: IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 476:67–74. 2020. View Article : Google Scholar : PubMed/NCBI
45	Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH and Ambudkar SV: MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Am J Cancer Res. 10:164–178. 2020.PubMed/NCBI
46	Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Küpper JH, Chen S, Guo L, Ceckova M and Staud F: Brivanib exhibits potential for pharmacokinetic drug-drug interactions and the modulation of multidrug resistance through the inhibition of human ABCG2 drug efflux transporter and CYP450 biotransformation enzymes. Mol Pharm. 16:4436–4450. 2019. View Article : Google Scholar : PubMed/NCBI
47	Bhardwaj B, Baidya ATK, Amin SA, Adhikari N, Jha T and Gayen S: Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer. SAR QSAR Environ Res. 30:457–475. 2019. View Article : Google Scholar : PubMed/NCBI
48	Zhang YK, Wang YJ, Lei ZN, Zhang GN, Zhang XY, Wang DS, Al-Rihani SB, Shukla S, Ambudkar SV, Kaddoumi A, et al: Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer Lett. 442:104–112. 2019. View Article : Google Scholar : PubMed/NCBI
49	Bar-Zeev M, Kelmansky D, Assaraf YG and Livney YD: β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. Eur J Pharm Biopharm. 133:240–249. 2018. View Article : Google Scholar : PubMed/NCBI
50	Ge C, Wang F, Cui C, Su X, To KKW, Wang X, Zhang H, Song X and Fu L: PCI29732, a Bruton's tyrosine kinase inhibitor, enhanced the efficacy of conventional chemotherapeutic agents in ABCG2-overexpressing cancer cells. Cell Physiol Biochem. 48:2302–2317. 2018. View Article : Google Scholar : PubMed/NCBI
51	Baxter DE, Kim B, Hanby AM, Verghese ET, Sims AH and Hughes TA: Neoadjuvant endocrine therapy in breast cancer upregulates the cytotoxic drug pump ABCG2/BCRP, and may lead to resistance to subsequent chemotherapy. Clin Breast Cancer. 18:481–488. 2018. View Article : Google Scholar : PubMed/NCBI
52	Tkach M and Théry C: Communication by extracellular vesicles: Where we are and where we need to go. Cell. 164:1226–1232. 2016. View Article : Google Scholar : PubMed/NCBI
53	Han L, Lam EW and Sun Y: Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. Mol Cancer. 18:592019. View Article : Google Scholar : PubMed/NCBI
54	Yousafzai NA, Wang H, Wang Z, Zhu Y, Zhu L, Jin H and Wang X: Exosome mediated multidrug resistance in cancer. Am J Cancer Res. 8:2210–2226. 2018.PubMed/NCBI
55	Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, Wang F, Chen Z, Cai J and Fu L: Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 18:1822019. View Article : Google Scholar : PubMed/NCBI
56	Bouvy C, Wannez A, Laloy J, Chatelain C and Dogné JM: Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. Leuk Res. 62:70–76. 2017. View Article : Google Scholar : PubMed/NCBI
57	Soekmadji C and Nelson CC: The emerging role of extracellular vesicle-mediated drug resistance in cancers: Implications in advanced prostate cancer. BioMed Res Int. 2015:4548372015. View Article : Google Scholar : PubMed/NCBI
58	Ma X, Chen Z, Hua D, He D, Wang L, Zhang P, Wang J, Cai Y, Gao C, Zhang X, et al: Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc Natl Acad Sci USA. 111:6389–6394. 2014. View Article : Google Scholar : PubMed/NCBI
59	Chen Y, Liu L, Li J, Du Y, Wang J and Liu J: Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract. 215:470–477. 2019. View Article : Google Scholar : PubMed/NCBI